Biopharma digital-marketing agency closerlook inc. announced the promotion of Amy Wolgemuth Bordoni to vice president, executive creative director.

Drug companies’ political committees have largely donated to Republican presidential campaigns since 1990, but that trend has noticeably reversed come the 2020 election cycle, according to a new report from the Center for Responsive Politics.

Geeta Vemuri is a trailblazer. Following her time as a Managing Partner at Baxter Ventures and Baxalta Ventures, Vemuri founded Agent Capital, a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Amidst the pandemic, the biopharma industry continues to surge ahead as BioSpace reviews companies that have made recent job announcement expansions.

The Coalition for Epidemic Preparedness Innovation (CEPI) plans to have two or three manufacturing plants for each vaccine, James Robinson, a longtime biopharma executive leading CEPI’S vast manufacturing push, said in an interview.

BIO 2020: Day 1 Kicked Off With New CEO, Focus on COVID-19 Published: June 9, 2020 By Alex Keown BioSpace   The annual Biotechnology Innovation Organization (BIO) meeting kicked off Monday […]

In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share.

Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results at the virtual ASCO 2020 event May 29-31.

Cambridge, Massachusetts-based Dyno Therapeutics came out of stealth mode with an official launch of the company’s proprietary CapsidMap platform.

There are more than 70 groups worldwide rushing to develop a vaccine against COVID-19, including Moderna, Johnson & Johnson, Pfizer and BioNTech, Novavax and many others. One of the groups that appears to be ahead of the race is not a commercial biopharma company: Oxford University’s Jenner Institute.